Login to Your Account



Clinic Roundup


Friday, May 20, 2011
Repligen Corp., of Waltham, Mass., received approval from the FDA to initiate a Phase I trial of RG3039, a potential treatment for spinal muscular atrophy, an inherited neurodegenerative disease. The company said the double-blind study will evaluate the pharmacokinetic and safety profile of escalating doses of RG3039 in as many as 40 healthy volunteers.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription